Best Practices in the Use of Incretin-based Therapies in the Management of Type 2 Diabetes
Released: December 20, 2016
Expires: December 20, 2018 (subject to change)
- CE for this activity will not be available after this date.
The management of type 2 diabetes mellitus (T2DM) remains a major clinical challenge as many patients continue to struggle with achieving therapeutic targets. Despite recent advances in T2DM therapies, optimal glycemic control is often not achieved. The goal of this activity is to improve knowledge and competency of nurse practitioners in addressing glycemic variability and cardiovascular considerations in patients with T2DM through optimal therapeutic management, with a particular focus on the optimal use of GLP-1 receptor agonists and DPP-4 inhibitors in individualized treatment regimens.
This is a recorded version of live presentations offered through the AANP Group Lecture Series. If you received credit for this activity by attending a live session, you may not receive duplicate credit for the same content in a different format.
After completion of this activity participants will be better able to:
- Outline differences and similarities in the mechanisms of action for both major classes of incretin-based therapies.
- Describe the effects of DPP-4 inhibitors on glycemic targets, including A1C levels and postprandial glucose.
- Discuss the effects of GLP-1 receptor agonists on glycemic targets, including A1C levels and postprandial glucose.
- Review the effects of GLP-1 receptor agonists and DPP-4 inhibitors on cardiovascular risk factors including lipid levels, blood pressure, and body weight.
Shannon Idzik, DNP, CRNP, FAANP
This activity was planned in accordance with AANP Accreditation Standards and Policies in cooperation with MCM Education. It is supported through an educational grant from Novo Nordisk, Inc. Dr. Idzik has no relevant affiliations to disclose.
This educational activity may contain opinions of the speaker from their personal experience. The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Credit: To complete the CE for this activity, review all the content, successfully complete on the online post-test and submit the online program evaluation.
Post Impact Survey:
Between 30 to 90 days after this activity is completed, AANP will send out an invitation to participate in a Post Impact Outcomes Survey (PI Survey) . Participation in the survey is optional and does not affect the credit earned. The PI surveys help measure the overall impact of the education content, see how the material impacts practice behaviors and what changes are being made. This anonymous information is crucial in helping the Education department improve current activities as well as guiding AANP in planning future CE activities.
For questions or more information concerning the AANP CE Center, or this online CE opportunity, please contact the AANP CE Center Manager at CECenter@aanp.org.
©2016. The American Association of Nurse Practitioners. All rights reserved. None of the content may be reproduced in any form without prior written permission from the publisher.